Developer docs
API playgroundTry for free, no card

Search company profiles

Even One Ventures

Full company profile

uuid00t5b1p

Namestring
Even One Ventures
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Even One Ventures is a San Francisco-based biotech venture builder founded in 2024-2025 by Sid Sijbrandij. The firm originates from Sijbrandij's personal experience navigating recurrent osteosarcoma after exhausting conventional treatment options: he assembled a team, pursued diagnostics, and ran individualized treatments in parallel. Even One Ventures was created to productize that patient-driven playbook by building biotech companies focused on rapidly making scientific advances accessible to patients who have run out of standard therapeutic options. The stated therapeutic focus spans four verticals — Oncology, Immune, Women's Health, and Rare Disease.

The underlying model is company creation rather than traditional fund investing. Even One Ventures builds portfolio biotech companies that develop individualized treatments and operate diagnostic and therapeutic programs in parallel for patients with high-unmet-need conditions. No specific pipeline assets, clinical-stage programs, or product launches are disclosed in the available material, and the portfolio appears to be in early formation. Distribution of any eventual treatments is intended to reach patients and healthcare providers globally through the portfolio companies.

The business model is venture-capital returns through equity ownership in the biotech companies the firm builds. There is no disclosed product pricing, management fee structure, fund close, or external investor base; the firm appears founder-led and independently operated. With 1-10 employees and no disclosed funding rounds, partnerships, or revenue, the company is at an earliest-stage operating posture, with awareness built primarily through founder networks, healthcare communities, and founder storytelling (including coverage in Century of Bio and on sytse.com).

Short descriptiontext

Even One Ventures is a San Francisco-based biotech venture builder founded by Sid Sijbrandij that creates portfolio companies developing individualized treatments for patients who have exhausted conventional options across oncology, immune, women's health, and rare disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biotech venture capital, life sciences investing, venture builder, healthcare startups, rare disease therapeutics
Industry1 code
PRIMARYFSANAAAH
Venture Studios / Company Builders
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Financial Vehicles52599
SIC code1 code
  • Investment Advice6282
Product category
Biotech Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeSubscription Recurring
Description

Even One Ventures generates returns through equity ownership in portfolio biotech companies that it builds and supports. The company was inspired by founder Sid Sijbrandij who built individualized treatments for his own cancer, demonstrating the potential for patient-driven biotech innovation.

evenone.ventures
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Even One Ventures is a biotech venture builder that starts and supports early-stage healthcare and life sciences companies focused on making scientific advances rapidly accessible to patients. The firm operates across Oncology, Immune, Women's Health, and Rare Disease, building companies that pursue diagnostics and run individualized therapeutic programs in parallel for patients who have exhausted conventional treatment options.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Even One Ventures is a biotech venture capital firm that builds and invests in biotech companies focused on making scientific advances accessible to patients. The firm operates across four therapeutic focus areas: Oncology, Immune, Women's Health, and Rare Disease. The company's portfolio consists of portfolio companies rather than traditional product offerings.

Product and service2 records
1Biotech Venture Building Services
CategoryBiotech Venture Capital
2Individualized Treatment Playbook
CategoryBiotech Operating Methodology
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Andreessen Horowitz's bio fund invests across the biotech and healthtech stack with a much larger platform and broader mandate. While it does not operate as a venture builder, it competes for the same founder talent and therapeutic-area opportunities as Even One Ventures.

TypeDirect peer
Description

ARCH Venture Partners invests early in deep-tech and biotech companies, often co-founding or seeding them. Its long-duration, science-heavy thesis and willingness to build companies from scratch make it a comparable peer for Even One Ventures.

TypeDirect peer
Description

Flagship Pioneering is the archetypal biotech venture builder, originating and growing companies (e.g., Moderna) around novel scientific platforms. Even One Ventures applies the same build-rather-than-buy model but focused specifically on individualized therapeutics for high-unmet-need indications, making Flagship the closest structural analog.

TypeBroad incumbent
Description

Khosla Ventures is a large venture firm with a meaningful biotech and healthcare practice that invests across stages. It is a broader incumbent versus Even One Ventures' specialized builder focus, but overlaps in early-stage science-driven investing.

TypeBroad incumbent
Description

GV invests across sectors including life sciences and biotech with a brand-driven, founder-friendly platform. It is a broader incumbent compared to Even One Ventures, but overlaps in backing high-conviction biotech founders at the earliest stages.

TypeDirect peer
Description

Foresite Capital is a healthcare and biotech-focused investment firm that backs early-stage companies across therapeutics and tools. Its concentrated healthcare thesis and willingness to form companies around novel science make it a comparable peer.

TypeDirect peer
Description

Versant Ventures is a healthcare-focused venture firm that both invests in and builds biotech companies across therapeutic areas. Its mix of de novo company creation and traditional investing aligns closely with Even One Ventures' builder-plus-investor positioning.

TypeDirect peer
Description

OrbiMed is a dedicated healthcare investment firm operating across the biotech, medtech, and diagnostics spectrum with substantial AUM. Even One Ventures competes for similar early-stage biotech opportunities, particularly in oncology and rare disease.

TypeDirect peer
Description

Section 32 is a biotech-focused venture fund founded by Bill Maris (former GV head) that invests across multiple therapeutic areas at early stages. Its thesis of identifying frontier biotech opportunities and supporting them through company formation is structurally similar to Even One Ventures' approach.

TypeDirect peer
Description

Atlas Venture is an early-stage biotech VC that builds and seeds new companies around emerging science, with a focus on rare diseases and platform technologies. Its builder-like approach to forming companies makes it a direct peer to Even One Ventures' model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Even One Ventures

Biotech Venture Capitalevenone.ventures

Even One Ventures is a San Francisco-based biotech venture builder founded by Sid Sijbrandij that creates portfolio companies developing individualized treatments for patients who have exhausted conventional options across oncology, immune, women's health, and rare disease.

What Even One Ventures does

Even One Ventures is a San Francisco-based biotech venture builder founded in 2024-2025 by Sid Sijbrandij. The firm originates from Sijbrandij's personal experience navigating recurrent osteosarcoma after exhausting conventional treatment options: he assembled a team, pursued diagnostics, and ran individualized treatments in parallel. Even One Ventures was created to productize that patient-driven playbook by building biotech companies focused on rapidly making scientific advances accessible to patients who have run out of standard therapeutic options. The stated therapeutic focus spans four verticals — Oncology, Immune, Women's Health, and Rare Disease.

The underlying model is company creation rather than traditional fund investing. Even One Ventures builds portfolio biotech companies that develop individualized treatments and operate diagnostic and therapeutic programs in parallel for patients with high-unmet-need conditions. No specific pipeline assets, clinical-stage programs, or product launches are disclosed in the available material, and the portfolio appears to be in early formation. Distribution of any eventual treatments is intended to reach patients and healthcare providers globally through the portfolio companies.

The business model is venture-capital returns through equity ownership in the biotech companies the firm builds. There is no disclosed product pricing, management fee structure, fund close, or external investor base; the firm appears founder-led and independently operated. With 1-10 employees and no disclosed funding rounds, partnerships, or revenue, the company is at an earliest-stage operating posture, with awareness built primarily through founder networks, healthcare communities, and founder storytelling (including coverage in Century of Bio and on sytse.com).

Even One Ventures firmographics

Firmographics
Name
Even One Ventures
Website
https://evenone.ventures
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Even One Ventures is a San Francisco-based biotech venture builder founded by Sid Sijbrandij that creates portfolio companies developing individualized treatments for patients who have exhausted conventional options across oncology, immune, women's health, and rare disease.
Ownership category
akta.pro rank

Even One Ventures industry classification

Industry
Product category
Biotech Venture Capital
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (52599)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAH
Venture Studios / Company Builders

Keywords

  • Biotech venture capital
  • Life sciences investing
  • Venture builder
  • Healthcare startups
  • Rare disease therapeutics

Where Even One Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Even One Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

Revenue model

  1. Venture Capital Returns: Even One Ventures generates returns through equity ownership in portfolio biotech companies that it builds and supports. The company was inspired by founder Sid Sijbrandij who built individualized treatments for his own cancer, demonstrating the potential for patient-driven biotech innovation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Even One Ventures product offering

Product offering

Core offering

Even One Ventures is a biotech venture builder that starts and supports early-stage healthcare and life sciences companies focused on making scientific advances rapidly accessible to patients. The firm operates across Oncology, Immune, Women's Health, and Rare Disease, building companies that pursue diagnostics and run individualized therapeutic programs in parallel for patients who have exhausted conventional treatment options.

Product overview

Even One Ventures is a biotech venture capital firm that builds and invests in biotech companies focused on making scientific advances accessible to patients. The firm operates across four therapeutic focus areas: Oncology, Immune, Women's Health, and Rare Disease. The company's portfolio consists of portfolio companies rather than traditional product offerings.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotech Venture Building Services
  • Individualized Treatment Playbook

Companies that use Even One Ventures

Customer profile

Segments1 record

Ideal customer profiles2 records

Even One Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Even One Ventures partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights4 records

Even One Ventures competitors and assessment

Company assessment

Broad incumbents

  • Andreessen Horowitz (a16z Bio): Andreessen Horowitz's bio fund invests across the biotech and healthtech stack with a much larger platform and broader mandate. While it does not operate as a venture builder, it competes for the same founder talent and therapeutic-area opportunities as Even One Ventures.
  • Khosla Ventures: Khosla Ventures is a large venture firm with a meaningful biotech and healthcare practice that invests across stages. It is a broader incumbent versus Even One Ventures' specialized builder focus, but overlaps in early-stage science-driven investing.
  • GV (Google Ventures): GV invests across sectors including life sciences and biotech with a brand-driven, founder-friendly platform. It is a broader incumbent compared to Even One Ventures, but overlaps in backing high-conviction biotech founders at the earliest stages.

Direct peers

  • ARCH Venture Partners: ARCH Venture Partners invests early in deep-tech and biotech companies, often co-founding or seeding them. Its long-duration, science-heavy thesis and willingness to build companies from scratch make it a comparable peer for Even One Ventures.
  • Flagship Pioneering: Flagship Pioneering is the archetypal biotech venture builder, originating and growing companies (e.g., Moderna) around novel scientific platforms. Even One Ventures applies the same build-rather-than-buy model but focused specifically on individualized therapeutics for high-unmet-need indications, making Flagship the closest structural analog.
  • Foresite Capital: Foresite Capital is a healthcare and biotech-focused investment firm that backs early-stage companies across therapeutics and tools. Its concentrated healthcare thesis and willingness to form companies around novel science make it a comparable peer.
  • Versant Ventures: Versant Ventures is a healthcare-focused venture firm that both invests in and builds biotech companies across therapeutic areas. Its mix of de novo company creation and traditional investing aligns closely with Even One Ventures' builder-plus-investor positioning.
  • OrbiMed: OrbiMed is a dedicated healthcare investment firm operating across the biotech, medtech, and diagnostics spectrum with substantial AUM. Even One Ventures competes for similar early-stage biotech opportunities, particularly in oncology and rare disease.
  • Section 32: Section 32 is a biotech-focused venture fund founded by Bill Maris (former GV head) that invests across multiple therapeutic areas at early stages. Its thesis of identifying frontier biotech opportunities and supporting them through company formation is structurally similar to Even One Ventures' approach.
  • Atlas Venture: Atlas Venture is an early-stage biotech VC that builds and seeds new companies around emerging science, with a focus on rare diseases and platform technologies. Its builder-like approach to forming companies makes it a direct peer to Even One Ventures' model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Even One Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Even One Ventures leadership team

Management profile

Number of profiles

Profiles1 record

Even One Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Even One Ventures M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Even One Ventures

What does Even One Ventures do?

Even One Ventures is a biotech venture builder that starts and supports early-stage healthcare and life sciences companies focused on making scientific advances rapidly accessible to patients. The firm operates across Oncology, Immune, Women's Health, and Rare Disease, building companies that pursue diagnostics and run individualized therapeutic programs in parallel for patients who have exhausted conventional treatment options.

Is Even One Ventures a public or private company?

Even One Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Even One Ventures founded?

Even One Ventures was founded in 2025. It employs 1 to 10 people.

Where is Even One Ventures based?

Even One Ventures is headquartered in San Francisco, United States, in the North America region.

How does Even One Ventures make money?

One revenue line is on record: venture Capital Returns.

Who are Even One Ventures's main competitors?

Broad incumbents on record are Andreessen Horowitz (a16z Bio), Khosla Ventures and GV (Google Ventures). Direct peers are ARCH Venture Partners, Flagship Pioneering, Foresite Capital, Versant Ventures, OrbiMed, Section 32 and Atlas Venture.

Does Even One Ventures have an API?

No public API is recorded for Even One Ventures.

What industry is Even One Ventures in?

Even One Ventures's product category is Biotech Venture Capital. Its primary akta.pro industry code is FSANAAAH, Venture Studios / Company Builders. Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales